VEGF-R inhibitors (UCB Celltech/ Johnson & Johnson)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameVEGF-R inhibitors (UCB Celltech/ Johnson & Johnson)
Drug Alias NameVEGF antagonist (Celltech Chiroscience)anticancer agent (Celltech Chiroscience)VEGF-R inhibitors (Celltech/Johnson & Johnson)KDR kinase inhibitor (Celltech Chiroscience)KDR kinase inhibitor (Celltech/J&J) +[7] 
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsVascular endothelial growth factor receptor 2 antagonistsAngiogenesis inhibitors
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsDiabetic RetinopathyNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUcb Celltech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUcb CelltechJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsDiabetic RetinopathyNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A